April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Comparison of Alcaftadine and Olopatadine Effects on Ocular Epithelium and Eosinophil Recruitment in a Murine Model of Allergic Conjunctivitis
Author Affiliations & Notes
  • Keith J. Lane
    Clinical R & D, ORA, Andover, Massachusetts
  • Santa J. Ono
    Biology, Univ. of Cincinnati, Cincinnati, Ohio
  • Footnotes
    Commercial Relationships  Keith J. Lane, None; Santa J. Ono, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6417. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Keith J. Lane, Santa J. Ono; Comparison of Alcaftadine and Olopatadine Effects on Ocular Epithelium and Eosinophil Recruitment in a Murine Model of Allergic Conjunctivitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6417.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Antihistamines constitute the first line of therapy for allergic conjunctivitis (AC), and are safe and effective in relieving the signs and symptoms ocular allergy. Often, seasonal and perennial allergy is described as a "two phase" condition consisting of immediate (or early) and delayed (or late) responses to allergen provocation. Recent evidence suggests that changes in conjunctival epithelium may underlie some aspects of the late phase. To examine a potential role for antihistamines in attenuating late phase AC symptoms, we compared two compounds, olopatadine and alcaftadine, for their ability to modify epithelial cell changes associated with AC at time points selected to reflect the late phase

Methods: : Studies employed a modified conjunctival allergen challenge (CAC) model. Sensitized mice were challenged with topical allergen with or without drug treatments. Treatment groups were assayed for acute phase (15 minutes) and delayed phase (24 hours) responses. Groups were scored for allergy symptoms (redness, itch, tearing, and edema) and for conjunctival mast cell number. Delayed-phase groups were also examined for eosinophil number and for tight junctional protein expression.

Results: : Olopatadine and alcaftadine treated animals had similar efficacy profiles and mast cell numbers, suggesting both were effective at ameliorating symptoms of the acute phase. In contrast, alcaftadine treated animals had significantly lower conjunctival eosinophil infiltration than either controls or olopatadine treated animals. Allergen challenge caused a significant decrease in expression of the junctional protein ZO-1, and this decrease was prevented by alcaftadine but not by olopatadine.

Conclusions: : Alcaftadine displays therapeutic properties beyond its antihistamine action. These include an ability to reduce conjunctival eosinophil recruitment, and a protective effect on epithelial tight junction protein expression. We propose that alcaftadine acts to attenuate late phase AC signs and symptoms via a stabilizing effect on conjunctival epithelial layer permeability.

Keywords: signal transduction: pharmacology/physiology 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.